NCT07282015 Real-world Secukinumab Outcomes in Canadian HS Patients
| NCT ID | NCT07282015 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Novartis Pharmaceuticals |
| Condition | Hidradenitis Suppurativa |
| Study Type | OBSERVATIONAL |
| Enrollment | 142 participants |
| Start Date | 2025-12-12 |
| Primary Completion | 2028-02-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 142 participants in total. It began in 2025-12-12 with a primary completion date of 2028-02-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.
Eligibility Criteria
Inclusion Criteria: 1. Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed. 2. Adult patients at the time of informed consent signature. 3. Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist. 4. Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit. 5. Patients who can understand written and spoken Canadian English or French. Exclusion Criteria: 1. Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation. 2. Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM. 3. Patients who have had any prior exposure to secukinumab (i.e., \>7 days prior to the baseline visit).
Contact & Investigator
Novartis Pharmaceuticals
STUDY DIRECTOR
Novartis Pharmaceuticals
Frequently Asked Questions
Who can join the NCT07282015 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Hidradenitis Suppurativa. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07282015 currently recruiting?
Yes, NCT07282015 is actively recruiting participants. Contact the research team at novartis.email@novartis.com for enrollment information.
Where is the NCT07282015 trial being conducted?
This trial is being conducted at Calgary, Canada, Calgary, Canada, Winnipeg, Canada, Fredericton, Canada and 11 additional locations.
Who is sponsoring the NCT07282015 clinical trial?
NCT07282015 is sponsored by Novartis Pharmaceuticals. The principal investigator is Novartis Pharmaceuticals at Novartis Pharmaceuticals. The trial plans to enroll 142 participants.